Recon: FDA declines to approve Ascendis’ hypoparathyroidism drug; Astellas to buy Iveric for $5.9B

[ad_1] Recon | 01 May 2023 |  By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US FDA advisory committee votes against plan…

Astellas Pharma to Buy Iveric Bio for About $5.9B

[ad_1] The Japanese drugmaker said it agreed to acquire Iveric bio for about $5.9 billion to strengthen its capabilities in the ophthalmology field. [ad_2] Source link